Teewinot Capital Advisers’s Bristol-Myers Squibb BMY Stock Holding History

Teewinot Capital Advisers’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,250	Closed	-$163K	–	40
2020 Q4	$163K	Sell	1,250 -750	-38%	-$46.1K	0.05%	29
2020 Q3	$63K	Hold	2,000	–	–	0.03%	25
2020 Q2	$60K	Hold	2,000	–	–	0.03%	28
2020 Q1	$815K	Sell	2,000 -2,000	-50%	-$122K	0.62%	14
2019 Q4	$2.35M	Buy	+4,000	New	+$229K	0.7%	17

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Teewinot Capital Advisers's BMY Position: Q2 2025 in Review

Teewinot Capital Advisers sold out of Bristol-Myers Squibb (BMY) in Q2 2025, closing a stake of 665,257 shares — an estimated $40.6M sold.

Teewinot Capital Advisers first reported a position in BMY in Q1 2025 and held it in 1 quarter. The position peaked at $40.6M in Q1 2025. 2,294 funds tracked by Wall St. Rank hold BMY as of Q2 2025.

Teewinot Capital Advisers reported no remaining Bristol-Myers Squibb position as of Q2 2025 after selling out during the quarter.
Teewinot Capital Advisers sold 665,257 Bristol-Myers Squibb shares in Q2 2025, an estimated $40.6M.
Teewinot Capital Advisers first reported a position in Bristol-Myers Squibb in Q1 2025 and held it in 1 quarter.
Teewinot Capital Advisers's Bristol-Myers Squibb position peaked at $40.6M in Q1 2025.
2,294 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2025.

Based on Teewinot Capital Advisers's 13F filing for Q2 2025, filed 14 Aug 2025.